Patent US4710381A successfully refreshed from Google Patents.
US4710381A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
Assignee: Blood Center of Southeastern Wisconsin
•
Filing: 1984-05-22
•
Granted: 1987-12-01
•
Expires: 2004-05-22
Abstract
Abstract A method for maintaining intact, non-degraded von Willebrand factor by preventing the action of calcium activated protease(s) responsible for degradation of the factor. The action of the calcium activated protease(s) may be avoided by removing the blood platelet source of the protease(s), by filtering or centrifugal separation, or by inactivating the protease with a chelating agent removing the calcium, by a protease inhibitor, or an alkylating agent.
Inventors
- 👤 Thomas J. Kunicki
- 👤 Robert R. Montgomery
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 18:43
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/755; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/829; Y10S530/83; Y10S530/831
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
78 words
A method of preparing blood or plasma for the extraction of intact, non-degraded FVIII/vWf, the blood or plasma containing FVIII/vWf and cellular sources of a calcium activated protease capable of cleaving the FVIII/vWf, said method including the step of removing substantially all cellular sources of the calcium activated protease from the blood or plasma while avoiding release of the protease from the cellular sources prior to or during removal of the cellular sources from the blood or plasma.
Claim 2
Independent Claim
78 words
A method of preparing blood or plasma for the extraction of intact, non-degraded FVIII/vWf, the blood or plasma containing FVIII/vWf and cellular sources of a calcium activated protease capable of cleaving the FVIII/vWf, said method including the step of removing substantially all cellular sources of the calcium activated protease from the blood or plasma while avoiding release of the protease from the cellular sources prior to or during removal of the cellular sources from the blood or plasma.
Claim 3
Dependent Claim
41 words
The method according to claim 1 wherein the blood or plasma includes platelets comprising a source of the calcium activated protease and wherein the method is further defined as removing substantially all platelets and platelet fragments from the blood or plasma.
Claim 4
Dependent Claim
20 words
The method according to claim 1 further defined as removing the cellular sources of the calcium activated protease by centrifugation.
Claim 5
Dependent Claim
41 words
The method according to claim 2 further defined as obtaining platelet poor plasma and thereafter removing substantially all the platelets and platelet fragments from the platelet poor plasma by a centrifugation comprising up to 20,000 g for up to 10 minutes.
Claim 6
Dependent Claim
41 words
The method according to claim 4 further defined as obtaining the platelet poor plasma by subjecting blood or plasma to a separating centrifugation employing forces lower than those used to remove the platelets and platelet fragments from the platelet poor plasma.
Claim 7
Dependent Claim
24 words
The method according to claim 1, further defined as removing the cellular sources of the calcium activated protease at least in part by filtration.
Claim 8
Dependent Claim
24 words
The method according to claim 6 further defined as passing plasma through a filter capable of retaining particles 0.1 micron in size and larger.
Claim 9
Dependent Claim
26 words
The method according to claim 6 further defined as passing plasma through a filter capable of retaining particles in a range of 0.1 to 0.45 microns.
Claim 10
Dependent Claim
19 words
The method according to claim 6 further defined as obtaining platelet poor plasma and filtering the platelet poor plasma.
Claim 11
Dependent Claim
34 words
The method according to claim 9 further defined as obtaining the platelet poor plasma by subjecting blood or plasma to a separating centrifugation at forces sufficiently low that rupture of the platelets is avoided.
Claim 12
Dependent Claim
31 words
The method according to claim 2 further defined as subjecting the blood or plasma to an antibody specific to the platelets and platelet fragments for removing the platelets and platelet fragments.
Claim 13
Dependent Claim
28 words
The method according to claim 11 further defined as subjecting the blood or plasma to antibodies, the producing hydridomas of which bear ATCC Registry Nos. HB8352 or HB8353.
Claim 14
Dependent Claim
22 words
The method according to claim 1, further defined as including the step of purifying FVIII/vWf from the blood or plasma so treated.
Claim 15
Independent Claim
76 words
A method of preparing blood or plasma for the extraction of intact, non-degraded FVIII/vWf, the blood or plasma containing platelets and FVIII/vWf, said platelets comprising a source of a calcium activated protease capable of cleaving the FVIII/vWf, said method including the steps of obtaining platelet poor plasma while avoiding release of the protease from the platelets and adding a chelating agent to the platelet poor plasma to prevent calcium in the plasma from activating the protease.
Claim 16
Independent Claim
76 words
A method of preparing blood or plasma for the extraction of intact, non-degraded FVIII/vWf, the blood or plasma containing platelets and FVIII/vWf, said platelets comprising a source of a calcium activated protease capable of cleaving the FVIII/vWf, said method including the steps of obtaining platelet poor plasma while avoiding release of the protease from the platelets and adding a chelating agent to the platelet poor plasma to prevent calcium in the plasma from activating the protease.
Claim 17
Dependent Claim
31 words
The method according to claim 14 further defined as adding a chelating agent having binding constant of 10 or greater expressed as the logarithm to the base 10 of the constant.
Claim 18
Dependent Claim
22 words
The method according to claim 14 further defined as adding a chelating agent selected from a class consisting of EDTA and EGTA.
Claim 19
Dependent Claim
21 words
The method according to claim 14 further defined as adding a quantity of chelating agent sufficient to chelate available calcium ions.
Claim 20
Dependent Claim
28 words
The method according to claim 16 further defined as adding at least 1 micromole of the selected chelating agent per 10 9 platelets in the platelet poor plasma.
Claim 21
Dependent Claim
20 words
The method according to claim 14 further defined as including the step of purifying FVIII/vWf from the plasma so treated.
Claim 22
Independent Claim
89 words
A method of obtaining intact, non-degraded FVIII/vWf from blood or plasma containing FVIII/vWF and cellular sources of a calcium activated protease capable of cleaving the FVIII/vWf, said method comprising the steps of: obtaining platelet poor plasma while avoiding release of the calcium activated protease from the cellular sources; passing the platelet poor plasma through a filter capable of retaining particles 0.1 micron in size and larger for removing substantially all cellular sources of the calcium activated protease from the platelet poor plasma; and purifying FVIII/vWf from the filtered plasma.
Claim 23
Independent Claim
89 words
A method of obtaining intact, non-degraded FVIII/vWf from blood or plasma containing FVIII/vWF and cellular sources of a calcium activated protease capable of cleaving the FVIII/vWf, said method comprising the steps of: obtaining platelet poor plasma while avoiding release of the calcium activated protease from the cellular sources; passing the platelet poor plasma through a filter capable of retaining particles 0.1 micron in size and larger for removing substantially all cellular sources of the calcium activated protease from the platelet poor plasma; and purifying FVIII/vWf from the filtered plasma.
References Cited (Backward Citations)
US29698A
Cited
USRE29698E
Cited
US4022758A
Cited
US4203891A
Cited
US4221780A
Cited
US4235881A
Cited
US4278594A
Cited
US4302445A
Cited
US4386068A
Cited
US4391746A
Cited
US4364861A
Cited
US4404132A
Cited
US4395396A
Cited
US4404131A
Cited
US4305871A
Cited
US4348384A
Cited
US4359463A
Cited
US4383989A
Cited
US4361509A
Cited
US4406886A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-11-30 | 1991-06-01 | 1991-12-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-11-30 | 1995-06-01 | 1995-12-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-11-30 | 1999-06-01 | 1999-12-01 | $7700.00 | Window Closed / Lapsed |